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ABSTRACT 
Colon cancer is the third leading type of cancer diagnosis in the United States (Siegel et al, 
2017). Common treatments include chemotherapy, which can be toxic to the patient and 
produce multiple adverse side effects (Sarkar, 2008). Combination therapies with 
chemotherapy drugs and other compounds have been reported to decrease tumor growth in 
breast and colon cancer by increasing efficacy of chemotherapeutic agents at lower doses, thus 
reducing off-target adverse effects (Borcherding et al, 2015; Chen et al 2017).  Both activation 
of Nrf2, a transcription factor that induces expression of anti-oxidant genes, and dopamine 
receptor agonists, have been shown to reduce tumor growth in multiple cancer types 
(Borcherding et al, 2015; Melba et al, 2013). Thus, we examined whether combining a common 
chemotherapy drug, Doxorubicin, with a Nrf2 activator, CDDO-ME, or a dopamine-type-1 
receptor agonist, Fenoldopam, improved efficacy of chemotherapy. Treatment of HT29 and 
HCT116 colorectal cancer cells in vitro with or CDDO-ME in conjunction with Doxorubicin 
augmented the effects of Doxorubicin alone, as determined by MTT assay. The results support 
that Doxorubicin had an effect on both cell lines above concentrations of 100 nM. However, 
Fenoldopam, a dopamine-type-1 receptor agonist, did not significantly affect cell viability. 
Therefore, the effects of Doxorubicin may be achieved at a lower dose when administered with 
CDDO-ME.  
 
INTRODUCTION 
Colorectal cancer (CRC) is the third highest 
diagnosed cancer and the second leading 
cause of cancer-related deaths across the 
United States. In fact, one in twenty people 
are diagnosed with this disease and over 
50,000 people died from CRC in 2017. 
Although the causes of a recent increase in 
CRC cases diagnosed in patients under the 
age of 50 are not well defined, risk factors 
include excess body weight, family history 
of CRC and past medical history of 
Inflammatory Bowel Disease (IBS) (Siegel et 
al, 2017; Janakiram & Rao, 2014). 
 
CRC is commonly treated with surgical 
removal of the tumor. However, most cases 
also require chemotherapy treatment to 
ensure any remaining cells are eliminated 
to prevent recurrent growth of a tumor 
(Chen et al, 2017; Sarkar, 2008).  Although 
current chemotherapy drugs used to treat 
CRC are effective, the side effects 
associated with these drugs are numerous 
and chemotherapeutic resistance is 
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becoming more of an issue in oncology 
(Sarkar, 2008). Doxorubicin, a widely used 
anti-cancer chemotherapy compound, 
often causes cardiotoxicity (Gustafson & 
Thamm, 2010). Therefore, the importance 
of discovering new treatment regimens for 
CRC to improve both the patient’s well-
being during treatment and their overall 
outcome is significant. 
 
Dopamine is primarily known as a 
neurotransmitter and hormone in the brain 
and central nervous system (CNS). 
However, Dopamine receptors (DR) are 
commonly located on cell membranes in 
blood vessels, the gastrointestinal tract and 
in the kidney (Borcherding et al, 2015). 
When the activity of these receptors is 
inhibited, the homeostatic mechanisms of 
these tissues are disrupted, leading to 
conditions like hypertension and gut 
hypermotility (Borcherding et al, 2015). 
However, activation of D1Rs with dopamine 
and dopamine-type-1 receptor (D1R) 
agonists has been shown to stabilize tumor 
blood vessel formation and decrease the 
size of tumors resulting from human breast 
and colon cancers in tumor bearing mice 
(Borcherding et al, 2015; Chen et al, 2017). 
The D1R agonist Fenoldopam, which is a 
drug commonly used to treat renal 
hypertension, was successful in suppressing 
not only breast cancer cell viability in vitro, 
but also breast cancer tumor growth in 
mice in vivo (Borcherding et al, 2015). 
Activation of the D1R/cGMP/protein kinase 
G (PKG) pathway caused apoptosis and 
necrosis of the cancer cells, which suggests 
that Fenoldopam could be utilized as a 
chemotherapeutic drug for tumor cells that 
express D1R receptors (Borcherding et al, 
2015). 
 
In addition to these findings, Dopamine also 
significantly inhibited tumor growth in mice 
when used in conjunction with 
chemotherapeutic drugs (Sarkar, 2008). 5-
FU is the most widely used CRC 
chemotherapy drug on the market (Chen et 
al, 2017). In a study using HT29 cells and 
human breast cancer cells, dopamine was 
shown to significantly augment the 
antitumorigenic effects of 5-FU and 
doxorubicin (Sarkar, 2008). These effects 
were attributed to dopamine’s ability to 
decrease vascular permeability 
factor/vascular endothelial growth factor 
(VPF/VEGF), which stabilized blood supply 
to the tumor cells (Sarkar, 2008). The 
findings of this study suggest that 
dopamine, and potentially other D1R 
agonists, could be useful adjuvants to 
chemotherapy agents in vitro (Sarkar, 
2008). 
 
Another target for CRC chemotherapeutic 
agents is Nuclear factor erythroid 2-related 
factor 2 (Nrf2), a transcription factor that 
alerts the cell to electrophilic and oxidative 
stress (Sadeghi, 2018). Expression of Nrf2 
stimulates the transcription of genes that 
encode proteins responsible for producing 
anti-inflammatory and anti-oxidant effects 
(Sadeghi, 2018). This signaling pathway, 
facilitated by the interactions between Nrf2 
and its primary inhibitor, Keap1, protects 
the cell from harmful substances and 
genetic changes, which can lead to cancer 
(Melba et al, 2013). However, there have 
been conflicting reports concerning the 
effectiveness of Nrf2 agonists as 
chemotherapy treatments (Melba et al, 
2013; Sporn & Liby, 2012). 
 
The conflicting studies have been attributed 
to the “good side and the dark side of Nrf2” 
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(Melba et al, 2013). As mentioned before, 
the Nrf2 pathway is one of the cell’s major 
defense mechanisms. Studies have shown 
that this defense mechanism protects 
healthy cells from damage caused by 
carcinogens, thereby classifying Nrf2 as a 
tumor suppressor protein (Melba et al, 
2013). However, this system can also be 
utilized by cancer cells to protect them from 
chemotherapeutic agents (Sporn & Liby, 
2012). The role of Nrf2 in cancer continues 
to be a common area of study in the 
research community. 
 
In order to build on the current 
understanding of CRC treatment options, 
the goals of this study were to test whether 
Doxorubicin, a chemotherapeutic agent 
that is known to be successful for treating 
breast cancer could also be effective in 
treating colorectal cancer. Additionally, 
Fenoldopam, a peripheral D1R agonist, and 
CDDO-ME, an Nrf2 activator, were used to 
treat CRC cells in conjunction with 
Doxorubicin to determine if the 
combination therapy could produce an 
additive or synergistic effect.  
 
MATERIALS AND METHODS 
Cell Culture 
HT29 and HCT116 cells were obtained from 
American Type Culture Collection (ATCC, 
Manassas, VA, USA). The cells were cultured 
in McCoy’s 5a growth media containing 10% 
fetal bovine serum (Atlanta Biologicals, 
Flowery Branch, GA, USA) and 5% Penicillin-
Streptomycin that were stored in a 37C 
incubator and were passaged every three to 
four days using sterile technique. They were 
also routinely evaluated for bacterial 
infection.  
 
 
 
Cell Plating 
HT29 and HCT116 cells were plated in sixty 
wells (6x10 grid) on a 96 well plate (two 
plates per cell line). Growth media was 
removed from the respective cell culture 
flasks and the cells were trypsinized with 3 
mL TrypLE Express for ten to fifteen minutes 
in a 37C incubator. Once the cells were 
mobile in the media, 3 mL of supplemented 
McCoy’s 5a growth media (described 
above) was added to each flask. The cells 
and the media were transferred to a 15mL 
conical and centrifuged for 3 minutes 
(100xg, 4C). The supernatant was removed 
and the cells were resuspended in 10 mL of 
supplemented McCoy’s 5a growth media. 
The number of cells per milliliter was 
calculated using a hemocytometer (10 uL 
cell solution, 10 uL Trypan Blue). Using the 
average number of cells per milliliter, the 
cell/media mixture was diluted to the 
proper amount in order plate 1000 cells per 
100 microliters in each well. 100 microliters 
of growth media was added to the outside 
rows. The plated cells were incubated in a 
37C incubator for twenty-four hours prior 
to treatment. 
 
Cell Treatments 
HT29 and HCT116 cells were treated with a 
range of doses of Doxorubicin (100 uL) 
combined with Fenoldopam (20 uM, 100 
uL) or CDDO-ME (HT29: 100 nM, 100 uL; 
HCT116: 200nM, 100 uL). After the plated 
cells had incubated for twenty-four hours, 
the growth media was removed. One 
column of six replicates was treated with 
either the control (McCoy’s 5a Growth 
Media, 2.5% FBS, 1% Pen-Strep with DMSO, 
100 uL), Fenoldopam or CDDO-ME as well 
as Doxorubicin. Doxorubicin was added to 
the plates in the following concentrations 
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for both the controls and the 
Fenoldopam/CDDO-ME treatment groups: 2 
nM, 20 nM, 200 nM and 2 uM. The cells 
were placed back in the 37C incubator for 
three days.  
 
Cell viability Assay 
After three days, MTT (20 uL) was added to 
the plates of HT29 and HCT116 cells treated 
with Doxorubicin and either Fenoldopam or 
CDDO-ME. The plates were incubated at 
37C for one hour. The media was aspirated 
off the cells and the crystals were 
solubilized with DMSO (100 uL). The plates 
were put on a plate shaker for three 
minutes and the absorbance was measured 
using a plate reader with an optical density 
of 570 nm.  
RESULTS 
Doxorubicin 
Doxorubicin had a significant effect on HT29 
cell viability at concentrations of 1nM, 
100nM and 1000nM (Figure 1, Figure 3). 
Doxorubicin had a significant effect on 
HCT116 cell viability at concentrations of 
100nM and 1000nM (Figure 2, Figure 4).  
 
Doxorubicin and Fenoldopam 
For both the HT29 and HCT116 cell lines, 
there was not a significant difference 
between the control group treated with 
only Doxorubicin and the test group treated 
with Doxorubicin and Fenoldopam at any 
concentrations of Doxorubicin (Figure 1, 
Figure 2).  
 
Doxorubicin and CDDO-ME 
For both cell lines, there was a significant 
difference between the control group 
treated with only Doxorubicin and the test 
group treated with Doxorubicin and CDDO-
ME at Doxorubicin concentrations of 0nM, 
1nM, 10nM and 100nM (Figure 3, Figure 4).   
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DISCUSSION 
Doxorubicin 
As mentioned before, Doxorubicin is a 
chemotherapeutic drug that is commonly 
used to treat breast cancer, however, its 
effectiveness in treating colon cancer has 
not been well researched (Sarkar, 2008). 
Therefore, one of the goals of this study 
was to determine whether the use of 
Doxorubicin is a viable treatment for 
colorectal cancer. The findings from the cell 
viability studies demonstrate that 
Doxorubicin does decrease the viability of 
colorectal cancer cells in vitro. These effects 
were not noted in concentrations below 
100nM, but were significant at both 100nM 
and 1000nM concentrations. 
 
Doxorubicin and CDDO-ME 
Studies of Nrf2 activators including CDDO-
ME have supported the ability of Nrf2 to 
function as a tumor suppressor by 
activating anti-inflammatory and anti-
oxidant systems of defense to protect the 
cells from carcinogens and other harmful 
cellular changes (Melba et al, 2013).  In 
addition, colorectal cancer progression is 
linked to inflammatory processes and 
patients with a history of IBS have a higher 
risk of developing colorectal cancer 
(Janakiram & Rao, 2014).  
 
The MTT cell viability assay indicates that 
CDDO-ME, an Nrf2 activator, had a 
significant inhibitory effect on HCT116 and 
HT29 cells as well as an additive effect with 
Doxorubicin. At concentrations below 
10nM, Doxorubicin did not appear to be 
effective in decreasing the viability of either 
HT29 or HCT116 cells. However, there was a 
significant difference between the cells 
treated with CDDO and those treated with 
the control at all concentrations of 
Doxorubicin except the highest dose. This is 
supported by the estimated OD50 of each 
treatment group. Because Doxorubicin 
appears to be ineffective below a 
concentration of 100nM, the significant 
difference between the treatment groups in 
this range can be attributed to CDDO-ME. 
At the concentration of 100nM Doxorubicin, 
there is a significant difference noted in 
both the control group and the CDDO-ME 
test groups when compared to their 
respective controls as well as when the two 
groups are compared to one another. 
Therefore, the decrease in cell viability at 
this concentration of Doxorubicin can be 
attributed to the additive effect of CDDO-
ME with Doxorubicin.  
 
In the HT29 cell line, there was less of an 
effect of CDDO in conjunction with 
Doxorubicin, which is demonstrated by the 
estimated OD50. Preliminary studies with 
HT29 cells had demonstrated that the 
concentration of CDDO used on HCT116 
cells had been too concentrated to solidify 
evidence supporting the additive effect of 
CDDO. Therefore, the concentration of 
CDDO used on HT29 cells in this study was 
half of that of the HCT116 cells. The results 
suggest that the concentration of CDDO 
used to treat HT29 cells may have been too 
low to demonstrate an equivalent additive 
effect.  
 
Doxorubicin and Fenoldopam 
In breast cancer cells, D1R agonist 
Fenoldopam alone was able to surmount an 
anti-tumor effect in vitro and in vivo 
(Borcherding et al, 2015). This was 
attributed to Fenoldopam’s ability to 
stabilize tumor angiogenesis and promote 
apoptosis (Borcherding et al, 2015). 
Therefore, this study sought to evaluate 
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whether the same conclusions might be 
true with colorectal cancer cells in vitro. 
Results from the cell viability assay of the 
control groups treated with Fenoldopam 
and Doxorubicin suggest that Fenoldopam 
did not have an effect on cell viability in 
vitro. While the data from the Doxorubicin 
and Fenoldopam experiments demonstrate 
significant difference with an increase in 
Doxorubicin concentration, there is not a 
statistical difference between the 
treatments with or without Fenoldopam. 
This suggests that the changes in cell 
viability were attributed to Doxorubicin only 
and not an additive or synergistic effect of 
Fenoldopam and Doxorubicin. However, 
because the mechanism of Fenoldopam in 
reference to inhibition of tumor growth also 
pertains to angiogenesis, further studies of 
Fenoldopam in vivo may provide more 
similar results to those of previous studies 
that demonstrated the therapeutic effects 
of this drug on breast cancer. Preliminary 
studies (data not shown) that demonstrated 
negative findings with combination of 
Dopamine and Doxorubicin might have also 
resulted for similar reasons to Fenoldopam. 
In this case, future in vivo studies with 
Dopamine might also be beneficial. 
 
 
CONCLUSIONS 
Based on the results of this study, it appears 
that Doxorubicin has the potential to be an 
effective treatment of colorectal cancer and 
should be further investigated in vivo to 
solidify this conclusion. Likewise, CDDO-ME 
appears to have both an individual and 
additive effect on colorectal cancer cells. In 
addition, Fenoldopam was not 
demonstrated to be an effective individual 
or additive treatment of either cell line.  
 
Although the MTT assay is effective in 
evaluating cell viability, it is not specific 
enough to evaluate whether the decrease 
in viability is a result of apoptosis or a 
decrease in cell proliferation.  
Because of this limitation, future 
experiments to determine whether 
apoptosis or decreased cell proliferation 
was the mechanism responsible for the 
noted decrease in cell viability would be 
beneficial. In addition, studies to determine 
the effects of these drugs in vitro using 
mouse models would be useful to evaluate 
whether the conclusions made in this study 
transcend to organ systems and to 
determine whether the negative results 
concerning Fenoldopam and Dopamine 
present differently in vivo. 
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